Last updated: September 8, 2026
Idursulfase, marketed as Elaprase by Takeda Pharmaceuticals, is an intravenous enzyme-replacement therapy for Hunter syndrome, or mucopolysaccharidosis type II. The product has a durable commercial position because Hunter syndrome is rare, treatment is chronic, and administration requires specialist infrastructure. Its principal risks are limited patient growth, high treatment cost, manufacturing complexity, regional reimbursement pressure, and potential competition from alternative iduronate-2-sulfatase products.
Elaprase sales grew rapidly after U.S. approval in 2006 and became a material rare-disease product for Shire. Product-level revenue disclosure became less transparent after Takeda acquired Shire in 2019. Takeda now reports Elaprase within broader or less granular revenue categories rather than consistently publishing a standalone global sales figure. No FDA-approved interchangeable or biosimilar idursulfase product had entered the U.S. market as of the latest publicly available FDA biologics listings reviewed for this analysis.
What is idursulfase and how does Elaprase work?
Idursulfase is a recombinant form of human iduronate-2-sulfatase, the lysosomal enzyme deficient in patients with Hunter syndrome. The drug is administered by intravenous infusion at 0.5 mg/kg once weekly. It is manufactured in a genetically engineered human cell line and is supplied as a sterile concentrate for infusion.
Hunter syndrome is an X-linked lysosomal storage disorder caused by mutations in the IDS gene. Accumulation of glycosaminoglycans produces progressive disease involving the skeleton, airways, cardiovascular system, hearing, and other organs. The disease primarily affects males, although rare symptomatic female cases have been reported.
Elaprase does not reverse established skeletal or neurologic damage. Its commercial value is tied to lifelong disease management, particularly in patients who tolerate weekly infusion and remain on therapy over many years.
| Attribute |
Idursulfase |
| Brand |
Elaprase |
| Active ingredient |
Idursulfase |
| Sponsor in the U.S. |
Takeda Pharmaceuticals |
| Original developer |
Shire |
| Indication |
Hunter syndrome, or MPS II |
| FDA approval |
July 24, 2006 |
| Administration |
Intravenous infusion |
| Standard dose |
0.5 mg/kg weekly |
| Biologic class |
Recombinant lysosomal enzyme |
| Regulatory designation |
Orphan drug and biologic |
| Primary commercial market |
Specialist rare-disease care |
The FDA approved Elaprase under accelerated approval based on urinary glycosaminoglycan reduction, with postmarketing obligations addressing clinical benefit and long-term outcomes (FDA, 2006).
How large is the idursulfase market?
The global idursulfase market is a high-price, low-volume market. Revenue depends more on diagnosis, treatment penetration, patient persistence, and reimbursement than on broad population expansion.
Published prevalence estimates for Hunter syndrome vary by geography and ascertainment method. Commercially treated patients represent only a subset of the estimated disease population because some patients remain undiagnosed, die early, have severe neurologic disease, or cannot obtain sustained access to enzyme replacement therapy.
The addressable market has several constraints:
- Hunter syndrome is rare and predominantly affects males.
- Weekly infusion creates a substantial treatment burden.
- Severe disease may limit treatment uptake or persistence.
- Reimbursement varies sharply across countries.
- Pediatric patients may transition between hospitals and infusion settings.
- Clinical trials and label expansions are difficult because patient numbers are small.
A reasonable commercial model is based on treated patients multiplied by annual net price. U.S. annual cost estimates for enzyme-replacement therapy in rare lysosomal disorders have commonly reached several hundred thousand dollars per patient, although actual net revenue depends on discounts, government pricing, contracts, site-of-care economics, and international price controls. A treated population of 1,000 to 2,000 patients at a blended annual net price of $250,000 to $400,000 would imply approximately $250 million to $800 million in annual revenue. This is an analytical range, not a reported Elaprase sales figure.
What is the financial trajectory of Elaprase?
Elaprase became one of Shire’s core rare-disease products after its U.S. launch. Shire’s historical annual reports reported Elaprase as a standalone product during periods when the drug was commercially material. Revenue benefited from orphan-drug pricing, chronic treatment, geographic expansion, and the absence of a direct U.S. competitor.
The financial trajectory can be divided into four periods.
| Period |
Commercial development |
Financial implication |
| 2006-2010 |
U.S. launch and European expansion |
Rapid revenue growth from a small base |
| 2011-2015 |
Broader diagnosis and treatment penetration |
Mature orphan-product revenue |
| 2016-2018 |
Shire portfolio expansion and market normalization |
Stable but less explosive growth |
| 2019-present |
Takeda ownership and reduced product-level disclosure |
Continued commercial contribution, limited public visibility |
Shire reported Elaprase sales of approximately $300 million in the early 2010s, with later annual figures fluctuating because of foreign-exchange effects, patient growth, and regional pricing. Product-level reporting was not consistent across every reporting period, and published figures should not be compared without adjusting for currency and reporting scope.
After Takeda completed its acquisition of Shire in January 2019, Elaprase was incorporated into Takeda’s rare-disease portfolio. Takeda’s reporting has focused on major growth products and broader business segments. Elaprase has not generally received the same level of standalone disclosure as products such as Entyvio, Takhzyro, or Vyvanse. The absence of a current standalone revenue figure does not establish a material sales decline; it reflects portfolio-reporting practice.
The product’s financial profile is likely characterized by:
- High gross margin relative to manufacturing cost per vial.
- High selling, general and administrative costs because patients require specialist support.
- Stable revenue from chronic use.
- Low unit-volume growth.
- Reimbursement and pricing pressure in mature markets.
- Exposure to infusion-center capacity and nurse-administration costs.
Takeda’s acquisition of Shire also changed the strategic context. Elaprase became part of a larger rare-disease platform with established regulatory, manufacturing, and commercial infrastructure. That scale supports supply continuity but can reduce the likelihood that management will allocate major development resources to a mature product with a narrow patient base.
When did idursulfase lose U.S. orphan exclusivity?
Elaprase received U.S. orphan-drug exclusivity in connection with its 2006 approval. Orphan exclusivity generally lasts seven years from approval, placing the core U.S. orphan-exclusivity expiration around July 2013.
Orphan exclusivity is separate from patent protection. It prevents FDA approval of the same drug for the same indication during the exclusivity period, subject to statutory exceptions, but it does not prevent all forms of competition. After orphan exclusivity ended, potential competitors could pursue approval through their own biologics applications or other applicable regulatory pathways.
| Protection or regulatory event |
Approximate date |
| FDA approval of Elaprase |
July 2006 |
| U.S. orphan exclusivity expiration |
July 2013 |
| European authorization |
2007 |
| Shire acquired by Takeda |
January 2019 |
| Current U.S. commercial status |
Marketed biologic |
The FDA classified Elaprase as a biologic product. As a result, U.S. follow-on competition is governed primarily by the Public Health Service Act and the biosimilar framework, not by the conventional small-molecule generic pathway.
What patents protect idursulfase?
The commercial protection for idursulfase has historically depended on a combination of patents, orphan exclusivity, manufacturing know-how, regulatory experience, and supply-chain execution.
Unlike small-molecule drugs, the key competitive barrier is not limited to a single active-ingredient patent. Important protected or difficult-to-replicate elements can include:
- Recombinant production of iduronate-2-sulfatase.
- Cell-line construction and selection.
- Protein expression and purification.
- Glycosylation and post-translational characteristics.
- Formulation and stability.
- Analytical characterization.
- Manufacturing controls.
- Clinical comparability data.
Public patent databases contain multiple patent families associated with idursulfase, recombinant enzyme production, formulations, and manufacturing methods. Patent terms vary by jurisdiction and may be affected by patent-term adjustment, terminal disclaimers, maintenance fees, and ownership changes. A single “idursulfase patent expiration date” is therefore not an accurate description of the product’s protection.
The commercial position is stronger than the remaining composition-of-matter position would suggest because a biosimilar sponsor must establish a high degree of similarity for a complex enzyme produced in a human cell system. Differences in glycosylation, potency, impurities, immunogenicity, and enzyme uptake can create regulatory and clinical-development risk.
What is the Orange Book and Purple Book status of Elaprase?
Elaprase is not a conventional Orange Book-listed small-molecule drug. The FDA’s Orange Book primarily identifies approved drug products and patent or exclusivity information for small-molecule applications. Biologic reference products and biosimilar information are tracked through the FDA’s Purple Book.
The FDA’s Purple Book framework identifies reference biologics, biosimilars, and interchangeable biosimilars. Elaprase is the reference biologic for idursulfase in the United States. No FDA-approved biosimilar or interchangeable biosimilar idursulfase product was identified in the publicly available Purple Book records reviewed for this analysis (FDA, 2024).
This distinction matters because a generic applicant cannot simply submit an abbreviated new drug application and rely on chemical equivalence. A competing idursulfase product would generally need to pursue a biologics pathway and demonstrate biosimilarity or obtain approval through another legally available route.
Which companies are challenging Elaprase?
The main competitive threat is not an active U.S. generic challenge. It is regional competition from other enzyme-replacement products and the possibility of future biosimilar development.
Hunterase and idursulfase beta
GC Biopharma developed Hunterase, also known as idursulfase beta, for Hunter syndrome. The product has been approved in South Korea and has been marketed or developed in selected international markets. Its existence demonstrates that another manufacturer can develop an iduronate-2-sulfatase product, but it does not automatically create U.S. substitution.
Hunterase and Elaprase may differ in cell substrate, manufacturing process, glycosylation pattern, clinical data, regulatory status, and market access. In jurisdictions where both products are available, hospitals and payers may evaluate price, supply reliability, infusion protocols, and evidence in pediatric and severe-disease populations.
Biosimilar developers
No publicly established U.S. biosimilar launch date exists for idursulfase. Potential developers face a small market, difficult analytical characterization, expensive clinical comparability work, and a concentrated prescriber base. Those factors can delay entry even after key patent and exclusivity barriers have expired.
What generic entry risks exist for idursulfase?
The near-term U.S. generic-entry risk is low. The more realistic risk is a delayed biosimilar or follow-on biologic entry in a price-sensitive market.
| Risk factor |
Impact on competition |
| Small patient population |
Limits return on development investment |
| Complex recombinant enzyme |
Raises analytical and manufacturing barriers |
| Weekly infusion |
Creates switching and adherence concerns |
| Established specialist networks |
Favors the incumbent |
| Long-term clinical experience |
Supports physician and payer familiarity |
| Expired orphan exclusivity |
Removes one major regulatory barrier |
| Patent-family uncertainty |
Requires jurisdiction-specific diligence |
| International competitors |
Creates regional, not necessarily U.S., pressure |
A biosimilar launch would likely begin in markets with centralized procurement or aggressive price controls. The United States could remain protected by commercial inertia, contracting, clinical familiarity, and limited sponsor interest even after legal exclusivity constraints weaken.
What patent litigation and settlement agreements affect Elaprase?
No major publicly established U.S. Paragraph IV litigation campaign involving an idursulfase generic was identified. Paragraph IV litigation is primarily associated with the Hatch-Waxman framework for small-molecule drugs. For Elaprase, the more relevant legal framework is the biologics patent-dispute process under the Biologics Price Competition and Innovation Act.
A future biosimilar applicant could trigger patent exchanges and litigation involving process, formulation, manufacturing, or use patents. The absence of a public settlement does not eliminate future dispute risk, but it means there is no established U.S. launch-at-risk timeline comparable to major small-molecule products.
How strong is the idursulfase patent estate?
The patent estate is likely strongest as a combined technology and manufacturing estate rather than as a single surviving molecule patent. Its practical strength rests on four factors:
- The biologic is difficult to reproduce analytically and commercially.
- Manufacturing know-how is not fully disclosed in patents.
- Clinical switching evidence is limited compared with mature small molecules.
- A biosimilar sponsor must build a viable product and supply chain for a small market.
Its principal weakness is that orphan exclusivity expired long ago and the product has been commercially established for nearly two decades. Older patent families may be expired or nearing expiration in major jurisdictions. Legal protection therefore declines over time, while manufacturing and market-access barriers remain.
How does Elaprase compare with alternative Hunter syndrome therapies?
| Product |
Sponsor |
Modality |
Administration |
Market position |
| Elaprase |
Takeda |
Recombinant idursulfase |
Weekly IV infusion |
Established global reference product |
| Hunterase/idursulfase beta |
GC Biopharma |
Recombinant idursulfase variant |
IV infusion |
Regional competitor |
| Hematopoietic or gene-based approaches |
Various developers |
Investigational or nonstandard approaches |
Depends on platform |
Potential long-term disruption |
Elaprase remains the established standard enzyme-replacement option in many markets. Gene therapy could represent a more disruptive future approach because it may reduce infusion frequency, but clinical development, durability, safety, and regulatory validation remain material barriers.
What is the FDA regulatory status of idursulfase?
The FDA approved Elaprase for patients with Hunter syndrome in 2006. The approval was based on reductions in urinary glycosaminoglycans and other clinical findings, with the FDA requiring postmarketing work because the disease is rare and traditional clinical endpoints are difficult to study.
The product’s label includes important safety considerations, particularly infusion-related reactions and hypersensitivity. Patients may develop antibodies, and severe allergic reactions require interruption or discontinuation of treatment. The need for supervised infusion adds cost and limits convenience relative to potential future subcutaneous or gene-therapy alternatives.
What are the main commercial scenarios for Elaprase?
Base case
Elaprase maintains a stable specialist market, with revenue supported by chronic treatment and patient retention. Growth is limited to diagnosis, geographic expansion, and modest increases in treated prevalence.
Downside case
Revenue declines gradually because of price concessions, regional competition from idursulfase beta, treatment discontinuation, and payer pressure. A biosimilar developer enters a major market and captures volume through discounts.
Upside case
Revenue increases through improved diagnosis, broader access in emerging markets, long-term use in pediatric patients, and stronger treatment penetration in countries where Hunter syndrome remains underdiagnosed.
The most likely commercial trajectory is mature and defensive rather than high growth. Elaprase can remain strategically valuable to Takeda even if it is no longer a leading growth asset because it generates recurring rare-disease revenue and uses established infrastructure.
Key Takeaways
- Idursulfase is a mature orphan biologic for Hunter syndrome, marketed globally as Elaprase.
- FDA approval occurred in July 2006, and U.S. orphan exclusivity expired around July 2013.
- Takeda owns the product following its acquisition of Shire in 2019.
- Historical Elaprase revenue reached the hundreds of millions of dollars annually, but Takeda does not consistently disclose current standalone sales.
- No FDA-approved idursulfase biosimilar or interchangeable biosimilar was identified in the reviewed Purple Book data.
- Hunterase, or idursulfase beta, is the main known commercial alternative in selected international markets.
- The remaining competitive barrier is driven more by biologic manufacturing, clinical comparability, and market access than by orphan exclusivity.
- The most probable financial outcome is stable-to-declining mature-product revenue, with limited unit growth and continuing exposure to reimbursement pressure.
FAQs
Is Elaprase still commercially available?
Yes. Elaprase remains an approved and marketed treatment for Hunter syndrome in the United States and other jurisdictions.
Is idursulfase a biosimilar?
No. Elaprase is the reference idursulfase biologic. Hunterase is a separate iduronate-2-sulfatase product, not automatically a U.S.-designated biosimilar to Elaprase.
How much does idursulfase treatment cost per year?
Annual cost can reach several hundred thousand dollars per patient, depending on body weight, dosing, country, reimbursement, discounts, and infusion costs. Public list prices are not equivalent to net manufacturer revenue.
Can idursulfase be administered at home?
Administration is generally by intravenous infusion under medical supervision because of the risk of infusion reactions. Home-infusion arrangements may be available in selected markets under controlled protocols.
Will gene therapy replace Elaprase?
Gene therapy could eventually reduce dependence on weekly enzyme replacement, but the timing depends on clinical durability, safety, regulatory approval, manufacturing scale, and payer acceptance. No approved gene therapy has displaced Elaprase as the established treatment standard.
References
-
European Medicines Agency. (2007). Elaprase: European public assessment report. https://www.ema.europa.eu/
-
Food and Drug Administration. (2006). FDA approves Elaprase for Hunter syndrome. U.S. Department of Health and Human Services. https://www.fda.gov/
-
Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services. https://purplebooksearch.fda.gov/
-
Shire plc. (2010-2018). Annual reports and financial statements. https://www.shire.com/
-
Takeda Pharmaceutical Company Limited. (2019-2024). Annual reports and financial results. https://www.takeda.com/investors/financial-results/
-
World Health Organization. (2022). Hunter syndrome and lysosomal storage disorders: Rare disease information. https://www.who.int/
